ALG-094295 / Aligos Therap - LARVOL DELTA

Preclinical Characterization of ALG-094295, a highly potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor targeting dimerization, internalization and degradation of PD-L1 (AACR 2026) - "In a humanized PD-L1 MC38 mouse model, a single oral dose of ALG-094295 (5 mg/kg) achieved PD-L1 target engagement comparable to INCB086550 (150 mg/kg PO). Daily oral dosing of ALG-094295 (50 or 150 mg/kg) in humanized PD-L1 MC38 mice over 21 days resulted in tumor growth inhibition equivalent to twice-weekly administration of durvalumab (10 mg/kg IV), with tumor size correlating with increased CD8⁺ T-cell infiltration... ALG-094295 is a highly potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor that promotes PD-L1 dimerization, internalization and degradation. ALG-094295 has the potential to overcome some limitations of antibody-based therapies due to potent PD-L1 blockade, oral delivery and novel mechanism of action."

Preclinical • Oncology • CD8